A Complete Genomics-led team isolated and sequenced the genomes of 34 circulating tumor cells from a woman with metastatic breast cancer.
VWR will act as the exclusive distributor for Biocept's liquid biopsy blood collection tubes everywhere in the world except China.
Asia Genomics will make CellMax's tests, including the CellMax-DNA Genetic Cancer Risk Test Assure and the CellMax-CRC Protect Test, available immediately.
New research has identified circulating cell subtypes with ties to better or worse outcomes in individuals with prostate cancer.
The company intends to use the funds to automate its platform and internationally commercialize its colorectal cancer detection assay.
While Cynvenio will still perform testing in its own lab right now, the firm's CEO said that interested labs could move the technology in house in the future if they desire.
The company also received a grant from the Maryland Innovation Initiative to help advance the device toward commercialization.
New data points to strong predictive ability for a ddPCR-based test of AR copy number, while other companies are pursuing tests that target expression of AR splice variants.
The company plans to submit a package to the FDA by the end of this year for use of the system in metastatic breast cancer patients, and then add other cancer types in the future.
The company's total revenues were $1.7 million, including $897,000 in commercial testing revenue. Its test volume was up 38 percent.
The Wall Street Journal looks into FamilyTreeDNA's handling of genetic genealogy searches by law enforcement.
In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.
MIT's Technology Review reports that researchers hope to develop a CRISPR-based pain therapy.
In Science this week: atlas of malaria parasites' gene expression across their life cycles, and more.